Cortex's CEO to Speak at the Rodman & Renshaw Techvest Healthcare Conference on October 26, 2004 at the Waldorf.IRVINE, Calif. -- Cortex Pharmaceuticals, Inc. (AMEX AMEX See: American Stock Exchange : COR) announced that Roger G. Stoll, Ph.D., Chairman, President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. will speak at the Rodman & Renshaw 6th Annual Techvest Healthcare Conference on Tuesday, October 26th at 9:25 AM (EST EST electroshock therapy. EST abbr. electroshock therapy ) in the Waldorf Astoria Hotel's Starlight Roof Center in New York City New York City: see New York, city. New York City City (pop., 2000: 8,008,278), southeastern New York, at the mouth of the Hudson River. The largest city in the U.S. , NY. Cortex is one of 241 invited companies to present at this conference to be held on October 26-28, 2004. Dr. Stoll will present data from the encouraging studies on the Company's lead Phase I AMPAKINE(R) product candidate, CX717, and discuss upcoming clinical milestones. He will also introduce the preclinical plans for the follow-on AMPAKINE compound, CX727. AMPAKINE compounds amplify the effects of glutamate, the primary excitatory ex·ci·ta·tive or ex·ci·ta·to·ry adj. Causing or tending to cause excitation. Adj. 1. excitatory - (of drugs e.g. neurotransmitter in the brain responsible for higher-order behaviors and cognitive activities, such as thinking, smelling, touching and memory. A live webcast of the presentation can be accessed by logging onto http://www.wallstreetwebcasting.com/webcast/rrshq4/cor and a replay will be available for 90 days following the conference. About Cortex Pharmaceuticals: Cortex, located in Irvine, California, is a neuroscience company focused on novel drug therapies for neurological and psychiatric disorders. The Company is pioneering a class of proprietary pharmaceuticals called AMPAKINE compounds, which act to increase the strength of signals at connections between brain cells. The loss of these connections is thought to be responsible for memory and behavior problems in Alzheimer's disease. Many psychiatric diseases, including schizophrenia, occur as a result of imbalances in the brain's neurotransmitter system. These imbalances may be improved by using the AMPAKINE technology. Cortex has alliances with N.V. Organon for the treatment of schizophrenia The concept of a cure as such in the treatment of schizophrenia remains controversial, as there is no consensus on the definition of "treatment" in the case of schizophrenia, although some criteria for the remission of symptoms have recently been suggested. and depression and with Les Laboratoires Servier for the development of AMPAKINE compounds to treat the neurodegenerative effects associated with aging and disease, including Mild Cognitive Impairment mild cognitive impairment (MCI), n memory loss generally associated with aging; does not affect normal independent functioning of an individual. , Alzheimer's disease and anxiety disorders. (http://www.cortexpharm.com/) |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion